Status:

RECRUITING

A RCT to Determine the Effect of ENDS Flavor Availability on Abstinence Within Smokers

Lead Sponsor:

RAI Services Company

Conditions:

Smoking

Tobacco

Eligibility:

All Genders

21-65 years

Phase:

NA

Brief Summary

The overall purpose of this study will be to assess primary combustible cigarette users' abstinence from smoking their usual brand of combustible cigarettes at the end of the study, when provided with...

Detailed Description

This will be a multi-site, open-label, randomized controlled trial to evaluate the rate of end-of-study abstinence of healthy adult consumers of combustible cigarettes when provided an electronic nico...

Eligibility Criteria

Inclusion

  • Able to read, understand, and are willing to sign an Informed Consent Form (ICF) and complete questionnaires written in English
  • Generally healthy male or female, between 21 and 65 years of age, inclusive, at the time of consent
  • All female (assigned at birth) candidate participants who agree during the pre-screener to receive and take a home pregnancy test prior to the SEV, and who affirm at the SEV that they are not pregnant or intending to become pregnant.
  • NOTE: Participants who identify as "intersex" or "unknown" during screening, will be offered the opportunity to receive a pregnancy test if they wish to take one.
  • Currently smoke at least 10 cigarettes on smoking days in the past 30 days
  • Smoke cigarettes regularly for at least 12 months
  • Smoke cigarettes on 15 or more of the past 30 days
  • Smoked at least 100 cigarettes in their lifetime prior to the screening and enrollment visit.
  • Must indicate smoking factory-made filtered menthol and/or non-menthol cigarettes as their primary nicotine product (Occasional use of other tobacco- or nicotine-containing products is acceptable)
  • Indicate a willingness to use ENDS
  • Agree to participate in the study and to abide by the study restrictions and requirements, as described in the informed concent form (ICF)

Exclusion

  • Female participants who are pregnant or breastfeeding or planning to become pregnant or start breastfeeding within the next 6 months based on self-report.
  • Female participants who self-report not using adequate methods to prevent pregnancy
  • Persons with pacemakers or other embedded electronic medical devices fitted
  • Persons who self-report heart disease, high blood pressure, diabetes, cancer, Chronic Obstructive Pulmonary Disease, emphysema, asthma or other lung/breathing conditions, a previous history of heart attack or stroke, or are taking medication for depression.
  • Persons who self-report they are allergic/sensitive to cosmetics or fragrances or to any ingredient listed in Vuse commercial products or similar products, including those listed below:
  • Carvone (L-)
  • Benzyl alcohol
  • Participants who have used ENDS, nicotine pouch or smokeless tobacco (i.e., chewing tobacco, snus, or snuff) products on 5 or more days in the past 30 days
  • Participants who have used ENDS, nicotine pouch or smokeless tobacco products more than 100 times in their lifetime
  • Participants who have used a nicotine replacement therapy (NRT) product or a prescription drug to help stop smoking (e.g., varenicline, bupropion) in the past 30 days.
  • Employee of a company that manufactures tobacco or ENDS products
  • Persons who are personally, have household members, or have close family or friends in litigation with a company that manufactures tobacco or ENDS products
  • Have taken part in a tobacco/nicotine research study in the past 30 days

Key Trial Info

Start Date :

September 17 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2026

Estimated Enrollment :

1950 Patients enrolled

Trial Details

Trial ID

NCT07172438

Start Date

September 17 2025

End Date

December 1 2026

Last Update

October 8 2025

Active Locations (27)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 7 (27 locations)

1

CRG Test America-Phoenix

Chandler, Arizona, United States, 85226

2

C&C-Fort Smith

Fort Smith, Arkansas, United States, 72908

3

Research America Orlando

Altamonte Springs, Florida, United States, 32701

4

C&C-Tampa

Clearwater, Florida, United States, 33761